Seropositivity of Toxoplasma gondii antibodies in rheumatoid arthritis patients under treatment with TNF-? antagonists

Authors

  • Hadeel Abed Dreaj
  • Huda Dhaher Hathal
  • Ahmed Abdul Hassan Abbas

DOI:

https://doi.org/10.51248/.v42i2.934

Keywords:

Rheumatoid arthritis, Toxoplasma gondii, TNF-? antagonist

Abstract

Introduction and Aim: Rheumatoid arthritis an autoimmune disease is the most frequent kind of inflammatory arthritis and a leading cause of disability in the United States. The study's goal was to determine whether or not individuals with Rheumatoid Arthritis were positive for Toxoplasma antibodies while receiving biological therapy.

 

Materials and Methods: By ELISA method Toxoplasma antibodies were investigates in serum of 100 RA patients under treatment with TNF-? antagonist from 4-6 months, and in serum from 100 healthy controls.

 

Results: A statistically significant difference was found between patients and controls in the proportion of Toxoplasma antibodies (IgM 6, IgG 16 positive individuals). There was no correlation identified between Toxoplasma antibody seropositivity and responsiveness to biological treatments or disease activity.

 

Conclusion: Toxoplasma antibody seropositivity may be associated with rheumatoid arthritis among Iraqi patients under biological drugs.

Author Biographies

Hadeel Abed Dreaj

Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq

Huda Dhaher Hathal

Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq

Ahmed Abdul Hassan Abbas

 

Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq

References

McLean-Tooke, A., Aldridge, C., Waugh, S., Spickett, G.P., Kay, L. Methotrexate, rheumatoid arthritis and infection risk—what is the evidence? Rheumatology. 2009; 48(8): 867-871.

Bechman, K., Subesinghe, S., Norton, S., Atzeni, F., Galli, M., Cope, A.P., et al., A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019; 58 (10): 1755-1766.

Germano, V., Cattaruzza, M.S., Osborn, J., Tarantino, A., Di Rosa, R., Salemi, S., et al. Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-? antagonists. Journal of Translational Medicine. 2014; 12 (77):1-10

Tian, A.L., Gu, Y.L., Zhou, N., Cong, W., Li, G.X., Elsheikha, H.M., et al., Seroprevalence of Toxoplasma gondii infection in arthritis patients in eastern China. Infect Dis Poverty. 2017; 6: 153.

Portes, J., Barrias, E., Travassos, R., Attias, M.,de Souza, W.Toxoplasma gondii Mechanisms of Entry Into Host Cells. Front Cell Infect Microbiol. 2020; 10: 294.

Kuba, R.H., Zghair, K.H., Alosami, M.H., Detection of Toxoplasma Antibodies and TNF-? in Rheumatoid Arthritis Patients Treated with Methotrexate. Iraqi Journal of Science, 2014; 55(4A): 1535-1540.

El-Sayed, N.M., Kishik, S.M., Fawzy, R.M. The current status of Toxoplasma gondii infection among Egyptian rheumatoid arthritis patients. Asian Pacific Journal of Tropical Disease. 2016; 6 (10): 797-801.

Salman, YJ., Mohammed, KA. Relationship between Toxoplasma gondii and arthritis among patients in Kirkuk city. Int J Curr Res Aca Rev. 2015; 3:175-187.

Bouratbine, A., Siala, E., Chahed, M.K., Aoun,K. Sero-epidimiological profile of toxoplasmosis in Northren Tunisia. Parasite. 2001; 8:61-66.

El-Henawy, A.A., Hafez, E.A.R., Nabih, N., Shalaby, N.M., Mashaly, M. Anti-Toxoplasma antibodies in Egyptian rheumatoid arthritis patients. Rheumatol Int. 2017; 37:785-790.

Ismail, KA. Reactivation of Toxoplasma gondii Infection in Patients under Biological Treatment by Antitumor Necrosis Factor Alpha (anti-TNF?). Clinical Trials and Drug Interactions. 2018; 1(1): 43-49.

Liu, Q., Wang, Z.D., Huang, S.Y., Zhu, X.Q. Diagnosis of toxoplasmosis and typing of Toxoplasma gondii. Parasit Vectors. 2015; 292:28(8): 1-14.

Hill, B., Wyatt, N., David, E. Cerebral Toxoplasmosis in a Rheumatoid Arthritis Patient on Immunosuppressive Therapy. Cureus. 2020; 12(6): e8547.

Gaffen, SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Current rheumatology reports. 2009;11(5):365-370.

Hosseininejad, Z., Sharif, M., Sarvi, S., Amouei, A., Hosseini, S.A., Nayeri Chegeni, T., et al., Toxoplasmosis seroprevalence in rheumatoid arthritis patients: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2018; 12(6): e0006545

Elsheikha, H.M. Congenital toxoplasmosis: priorities for further health promotion action. Public Health. 2008;122: 335-353.

Nowakowska, D., Wujcicka, W., Sobala, W., Spiewak, E., Gaj, Z., Wilczyñski, J. Age-associated prevalence of Toxoplasma gondii in 8281 pregnant women in Poland between 2004 and 2012. Epidemiol Infect. 2014;142: 656-661.

Wilking, H., Thamm, M., Stark, K., Aebischer, T., Seeber, F. Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. Sci Rep. 2016;6: 22551.

Fischer, S., Agmon-Levin, N., Shapira, Y., Porat Katz, B.S., Graell, E., Cervera, R., et al., Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. Immunol Res. 2013;56: 287-292.

Downloads

Published

2022-05-01

How to Cite

1.
Dreaj HA, Hathal HD, Hassan Abbas AA. Seropositivity of Toxoplasma gondii antibodies in rheumatoid arthritis patients under treatment with TNF-? antagonists. Biomedicine [Internet]. 2022 May 1 [cited 2022 Nov. 27];42(2):314-7. Available from: https://biomedicineonline.org/home/article/view/934

Issue

Section

Original Research Articles

Plum Analytics